Chemical compound in the ergot family of alkaloids
Ergotamine Trade names Ergomar, others Other names 2'-Methyl-5'α-benzyl-12'-hydroxy-3',6',18-trioxoergotaman; 9,10α-Dihydro-12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione AHFS /Drugs.com Monograph License data
Pregnancy category Routes of administration Oral ATC code Legal status
Bioavailability Intravenous: 100%,[ 6] Intramuscular: 47%,[ 7] Oral: <1%[ 8] (Enhanced by co-administration of caffeine[ 6] ) Metabolism Liver [ 7] Elimination half-life 2 hours[ 7] Excretion 90% Bile duct [ 7]
(6aR ,9R )-N -((2R ,5S ,10aS ,10bS )-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H -oxazolo[3,2-a ]pyrrolo[2,1-c ]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg ]quinoline-9-carboxamide
CAS Number PubChem CID IUPHAR/BPS DrugBank ChemSpider UNII KEGG ChEBI ChEMBL PDB ligand CompTox Dashboard (EPA ) ECHA InfoCard 100.003.658 Formula C 33 H 35 N 5 O 5 Molar mass 581.673 g·mol−1 3D model (JSmol )
C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C
InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1
Y Key:XCGSFFUVFURLIX-VFGNJEKYSA-N
Y
N Y (what is this?) (verify)
Ergotamine , sold under the brand name Ergomar among others, is an ergopeptine and part of the ergot family of alkaloids ; it is structurally and biochemically closely related to ergoline .[ 9] It is structurally similar to several neurotransmitters , and it acts as a vasoconstrictor . It is used for acute migraines , sometimes with caffeine as the combination ergotamine/caffeine .[ 10] [ 11]
Medicinal use of ergot fungus began in the 16th century, for the induction of childbirth ; but dosage uncertainty discouraged its use. It has been used to prevent post-partum hemorrhage (bleeding after childbirth). It was first isolated from the ergot fungus by Arthur Stoll , at Sandoz in 1918, and was marketed as Gynergen in 1921.[ 12]
^ "Prescribing medicines in pregnancy database" . Therapeutic Goods Administration (TGA) . 21 June 2022. Retrieved 20 May 2024 .
^ a b "Ergomar- ergotamine tartrate tablet, orally disintegrating" . DailyMed . 8 September 2012. Retrieved 20 May 2024 .
^ "Ergotamine (Ergomar) Use During Pregnancy" . Drugs.com . 6 May 2024. Retrieved 20 May 2024 .
^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 15 August 2023 .
^ "Ergomar sublingual- ergotamine tartrate tablet" . DailyMed . 25 October 2022. Retrieved 18 May 2024 .
^ a b Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology . 30 (3): 331–334. doi :10.1007/BF00541538 . PMID 3732370 . S2CID 37538721 .
^ a b c d Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". In Olesen J, Tfelt-Hansen P, Welch KM (eds.). The Headaches . New York: Raven Press. pp. 313–22.
^ Ibraheem JJ, Paalzow L, Tfelt-Hansen P (December 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers" . British Journal of Clinical Pharmacology . 16 (6): 695–699. doi :10.1111/j.1365-2125.1983.tb02243.x . PMC 1428366 . PMID 6419759 .
^ Index Nominum 2000: International Drug Directory . Taylor & Francis. 2000. pp. 397–. ISBN 978-3-88763-075-1 .
^ "Cafergot- ergotamine tartrate and caffeine tablet, film coated" . DailyMed . U.S. National Library of Medicine. Archived from the original on 16 January 2014.
^ "Migergot- ergotamine tartrate and caffeine suppository" . DailyMed . 29 November 2022. Retrieved 18 May 2024 .
^ A. J. Giannini, A. E. Slaby. Drugs of Abuse . Oradell, New Jersey: Medical Economics Books, 1989.